The coronary stents market is experiencing significant growth due to the rising prevalence of cardiovascular diseases (CVDs) worldwide. Coronary stents are widely used in percutaneous coronary interventions (PCI) to restore blood flow in patients suffering from coronary artery disease (CAD). Technological advancements, increasing adoption of minimally invasive procedures, and the growing geriatric population contribute to market expansion.
Get a Sample PDF copy of Coronary Stents Market @ https://www.reportsinsights.com/sample/664518
The global coronary stents market was valued at USD XX billion in 2023 and is projected to reach USD XX billion by 2030, growing at a CAGR of XX% from 2024 to 2030. The market’s growth trajectory is driven by innovation in drug-eluting stents (DES), bioresorbable scaffolds, and the increasing incidence of cardiovascular conditions.
Coronary stents are small, expandable mesh tubes placed in narrowed or blocked coronary arteries to keep them open and ensure continuous blood flow. These stents are primarily used in PCI procedures and are categorized into three main types:
Bare Metal Stents (BMS): Traditional stents without a drug coating, primarily used to reduce the risk of restenosis.
Drug-Eluting Stents (DES): Coated with medication to prevent the recurrence of arterial blockage.
Bioresorbable Vascular Scaffolds (BVS): Designed to dissolve over time, reducing long-term complications.
The coronary stents market can be segmented based on product type, material, end-user, and region.
Bare Metal Stents (BMS)
Drug-Eluting Stents (DES)
Bioresorbable Vascular Scaffolds (BVS)
Metallic Stents (Cobalt Chromium, Stainless Steel, Platinum Chromium)
Polymer-based Stents
Hospitals
Specialty Clinics
Ambulatory Surgical Centers (ASCs)
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Access full Report Description, TOC, Table of Figure, Chart, etc. @Â https://www.reportsinsights.com/industry-forecast/coronary-stents-market-statistical-analysis-664518
CVDs remain the leading cause of death worldwide, with 17.9 million deaths annually (WHO). The increasing incidence of CAD boosts demand for coronary stents.
The development of next-generation drug-eluting stents, biodegradable stents, and polymer-free DES has improved patient outcomes and reduced restenosis rates.
Aging populations are at a higher risk of cardiovascular diseases, leading to an increased need for coronary stents.
PCI procedures offer faster recovery, reduced hospital stays, and lower complications, driving stent adoption.
Governments and insurance providers are expanding coverage for coronary stent procedures, improving accessibility.
Advanced stents, particularly DES and BVS, are expensive, making affordability a key challenge, especially in emerging economies.
The approval process for new stents is rigorous, requiring extensive clinical trials, which delays market entry.
Though rare, complications like stent thrombosis, artery re-narrowing (restenosis), and allergic reactions can impact market growth.
Coronary artery bypass grafting (CABG) and medications provide alternative treatment options, limiting stent adoption.
Coronary stents are primarily used in PCI to treat CAD and restore normal blood flow in arteries affected by atherosclerosis.
In cases of acute myocardial infarction (AMI), stents are deployed urgently to prevent fatal blockages.
Patients with high cholesterol, hypertension, or diabetes often receive stents as preventive measures against future cardiac events.